Skip to main content
    B

    Brainsway Ltd (BWAY)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $11.82
    +0.31 (+2.69%)

    Market Cap: $463.31M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(24/30)
    Avg Surprise
    +18.65%
    Streak
    14 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.09
    Range$0.07 - $0.12
    3 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.090.0%
    60d ago$0.10-8.7%
    30d ago$0.090.0%
    7d ago$0.090.0%
    Current$0.09
    Revenue Consensus
    $18M
    Range$17M - $18M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.10
    Range$0.06 - $0.17
    3 analysts
    Revenue Consensus
    $20M
    Range$20M - $21M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.10---
    Sep 26EST
    		-$0.09---
    Jun 26
    Reported Aug 12
    		$0.14$0.10+40.00%Beat+366.7%
    Mar 26
    Reported May 13
    		$0.06$0.05+20.00%Beat+500.0%
    Dec 25
    Reported Mar 11
    		$0.06$0.05+39.91%Beat+59.5%
    Sep 25
    Reported Nov 11
    		$0.02$0.02+0.00%Beat+100.0%
    Jun 25
    Reported Aug 13
    		$0.03$0.02+50.00%Beat+200.0%
    Mar 25
    Reported May 13
    		$0.01$0.01+0.00%Beat+49.3%
    Dec 24
    Reported Mar 11
    		$0.04$0.02+100.00%Beat+426.3%
    Sep 24
    Reported Nov 12
    		$0.01$0.01+0.00%Beat+150.0%
    Jun 24
    Reported Aug 6
    		$0.01$-0.01+200.00%Beat+150.0%
    Mar 24
    Reported May 8
    		$0.01$-0.01+167.00%Beat+116.8%
    Dec 23
    Reported Mar 6
    		$0.01$-0.01+176.00%Beat+103.2%
    Sep 23
    Reported Nov 15
    		$-0.02$-0.02+0.00%Beat+71.4%
    Jun 23
    Reported Aug 9
    		$-0.02$-0.04+50.00%Beat+50.0%
    Mar 23
    Reported May 17
    		$-0.04$-0.05+20.00%Beat-33.3%
    Dec 22
    Reported Mar 15
    		$-0.24$-0.13-84.62%Miss-500.0%
    Sep 22
    Reported Nov 16
    		$-0.07$-0.03-133.33%Miss-250.0%
    Jun 22
    Reported Aug 10
    		$-0.04$-0.03-33.33%Miss-33.3%
    Mar 22
    Reported May 11
    		$-0.03$-0.04+25.00%Beat+40.0%
    Dec 21
    Reported Mar 9
    		$-0.04$-0.05+20.00%Beat+0.0%
    Sep 21
    Reported Nov 17
    		$-0.02$-0.03+33.33%Beat+0.0%
    Jun 21
    Reported Aug 11
    		$-0.03$-0.03+0.00%Beat-200.0%
    Mar 21
    Reported May 20
    		$-0.05$-0.03-66.67%Miss+83.3%
    Dec 20
    Reported Mar 24
    		$-0.04$-0.07+42.86%Beat+20.0%
    Sep 20
    Reported Nov 18
    		$-0.02$-0.03+33.33%Beat+83.3%
    Jun 20
    Reported Aug 12
    		$-0.01N/A+83.33%Beat+97.1%
    Mar 20
    Reported Jun 24
    		$-0.30$-0.15-100.00%Miss-172.7%
    Dec 19
    Reported Mar 23
    		$-0.05$-0.06+16.67%Beat+58.3%
    Sep 19
    Reported Nov 25
    		$-0.12$-0.12+0.00%Beat-35.1%
    Jun 19
    Reported Aug 26
    		$-0.34$-0.13-161.54%Miss-209.9%
    Mar 19
    Reported May 29
    		$-0.11$-0.14+21.43%Beat-78.3%
    Dec 18
    Reported Feb 27
    		$-0.12$0.00N/AMiss+28.4%
    Sep 18
    Reported Sep 30
    		$-0.09N/AN/ABeat+28.6%
    Jun 18
    Reported Jun 30
    		$-0.11N/AN/ABeat-216.1%
    Mar 18
    Reported Mar 31
    		$-0.06N/AN/ABeat+52.9%
    Dec 17
    Reported Dec 31
    		$-0.17N/AN/ABeat-63.6%
    Sep 17
    Reported Sep 30
    		$-0.12N/AN/ABeat-
    Jun 17
    Reported Jun 30
    		$-0.03N/AN/ABeat-
    Mar 17
    Reported Mar 31
    		$-0.13N/AN/ABeat-
    Dec 16
    Reported Dec 31
    		$-0.10N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio41.65EV/EBITDAN/A
    Price/FCF53.65xFCF Yield1.86%
    Profitability
    Profit Margin15.60%Operating Margin14.00%
    ROE12.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage4.74x
    Current Ratio3.59xQuick Ratio3.27x
    Trading Statistics
    Beta0.10Avg Volume111.20K
    52-Week High$17.4052-Week Low$7.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.82
    SMA 20$12.57
    SMA 50$13.82
    SMA 200$13.88
    EMA 10$11.95
    EMA 20$12.44
    EMA 50$13.41
    EMA 200$13.12

    MACD

    Line: -0.65Signal: -0.62Hist: -0.03

    ADX

    ADX: 15.9+DI: 24.3-DI: 26.8

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down80.0
    PSAR$12.35

    Bollinger Bands

    Upper Band$14.25
    Lower Band$10.90
    %B Position2661%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    36.9

    Momentum Oscillators

    Stoch %K13.4
    Stoch %D11.2
    Williams %R-82.9
    ROC (10d)-6.2%
    Momentum-0.78
    CCI (20d)-79.0
    MFI (14d)26.4

    Volatility Measures

    ATR (14d)$0.57(4.8%)
    StdDev (20d)0.84
    Hist Vol35.4%(Moderate)

    Volume Flow

    VWAP$11.70
    OBV1.8M
    AD Line-325.9M
    CMF (20d)-0.103

    Volume Metrics

    Avg Vol (20d)116.2K
    Vol Ratio0.9x
    VWMA (20d)$12.46

    Pivot Points

    R3$12.03
    R2$11.91
    R1$11.71
    Pivot Point$11.59
    S1$11.39
    S2$11.27
    S3$11.07

    Advanced Oscillators

    TSI-38.17
    Ultimate Osc42.6
    KST-151.15

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$17.40M$15.53M$14.54M$13.51M$12.63M$11.54M$11.41M$10.50M$10.01M$9.10M$9.03M$8.30M
    Cost of Revenue$4.42M$3.86M$3.43M$3.35M$3.13M$2.93M$2.90M$2.78M$2.47M$2.28M$2.29M$2.13M
    Gross Profit$12.99M$11.68M$11.12M$10.16M$9.50M$8.61M$8.51M$7.72M$7.54M$6.81M$6.74M$6.17M
    Operating Expenses$10.55M$9.67M$9.20M$8.91M$8.92M$8.03M$8.08M$7.44M$6.95M$6.72M$-3,363,000$6.30M
    R&D$3.27M$2.88M$2.53M$2.40M$2.34M$2.33M$2.04M$1.81M$1.71M$1.63M$1.43M$1.54M
    SG&A$7.16M$1.86M$1.57M$1.78M$1.64M$1.54M$1.56M$1.52M$1.44M$1.27M$11.56M$1.16M
    Operating Income$2.43M$2.00M$1.92M$1.25M$578,000$576,000$431,000$281,000$586,000$93,000$10.10M$-133,000
    Interest Income$1.41M$724,000$1.06M$1.13M$2.30M$1.27M$532,000$830,000$518,000$618,000$0$175,000
    Interest Expense$894,093$319,000$433,692$571,000$784,000$586,000$1.05M$374,000$401,000$428,000$160,000$213,000
    Income Before Tax$2.97M$2.41M$2.54M$1.81M$2.10M$1.26M$1.74M$737,000$703,000$283,000$-37,000$-171,000
    Income Tax Expense$211,571$120,000$-392,000$242,000$70,000$157,000$188,000$75,000$103,000$172,000$-164,000$59,000
    Net Income$2.76M$2.29M$2.93M$1.57M$2.03M$1.11M$1.55M$662,000$600,000$111,000$127,000$-230,000
    EBITDA$2.88M$3.19M$3.32M$2.78M$3.27M$2.24M$1.07M$1.56M$1.40M$1.03M$1.58M$374,000
    EBIT$2.43M$2.73M$2.97M$2.38M$2.88M$1.85M$431,000$1.11M$1.10M$711,000$1.25M$42,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BWAY

    News

    Brainsway Q3 2026 Earnings Date and Estimates

    Brainsway (BWAY) is projected to release its Q3 2026 earnings on Tuesday, November 10, 2026, before market open...

    MarketBeat•10/14/26•Somewhat-Bullish

    BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

    BrainsWay Ltd. announced that its SWIFT™ Accelerated Deep TMS™ protocol now has favorable coverage for over 70 million covered lives in the U.S. This expansion highlights increasing adoption pathways for their...

    GlobeNewswire•10/13/26•Bullish

    BrainsWay expands U.S. insurance coverage to 70 million lives By Investing.com

    BrainsWay Ltd. announced that its SWIFT Accelerated Deep TMS protocol is now covered by insurance policies for over 70 million people in the United States. This expansion signifies a growing acceptance of Deep...

    Investing.com Canada•10/13/26•Bullish

    BrainsWay expands U.S. insurance coverage to 70 million lives

    BrainsWay Ltd. announced that its SWIFT Accelerated Deep TMS protocol is now covered by insurance policies for over 70 million people in the United States. This expansion reflects growing favorable medical policies...

    Investing.com•10/13/26•Bullish

    With three FDA-cleared indications, BrainsWay (BWAY) reports expanding U.S. treatment coverage.

    BrainsWay Ltd. (BWAY) has announced a significant expansion in U.S. medical policy coverage for its SWIFT Accelerated Deep TMS™ protocol, now reaching over 70 million covered lives. This expansion...

    Stock Titan•10/13/26•Bullish

    BWAY Valuation and Fair Value

    P/E
    41.6x
    Forward P/E
    17.9x
    P/FCF
    53.6x
    P/B
    3.0x
    See GNG's fair value

    BWAY Profitability: Margins, ROIC and FCF

    Gross margin
    75.3%
    Operating margin
    14.0%
    Net margin
    15.6%
    ROE
    12.8%
    FCF margin
    7.2%
    FCF yield
    1.9%

    BWAY Competitors

    CompanyTicker
    Tilray IncTLRY
    National Research CorpNRC
    AngioDynamics IncANGO
    Cerus CorporationCERS
    Senseonics Holdings, Inc. Common StockSENS
    Neurogene IncNGNE
    XOMA CorpXOMA
    KamadaKMDA

    Sector: Healthcare

    BWAY Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    BWAY Bull Case vs Bear Case

    Bull case

    • BWAY grew quarterly revenue 35.4% year over year.

    Bear case

    • BWAY trades at 41.6x trailing earnings.

    BWAY Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    31.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About BWAY

    Does BWAY pay dividends?

    Brainsway Ltd (BWAY) does not currently pay a regular dividend.

    What is BWAY's P/E ratio?

    Brainsway Ltd has a price-to-earnings (P/E) ratio of 41.65.

    What is BWAY's market cap?

    Brainsway Ltd (BWAY) has a market capitalization of $463.31M with a current stock price of $11.82.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In